{"artifact":{"id":"experiment_proposal-e5b45059-f361-45a3-8ed0-f972ded65df8","artifact_type":"experiment_proposal","entity_ids":"[\"Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-0021 Therapeutic Window in AD\"]","title":"Experiment Proposal (crux): Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-0021 Therapeutic Window in AD — hypothesis chain depends on multiple unproven causal links with no evidence for ","quality_score":0.5,"created_by":"crux_generator:theorist","provenance_chain":"[]","content_hash":"127c4bde46895f17c674b5d89e1f21540fec2f3197439d9ff3db94cf6b836dfe","metadata":{"aims":["Define molecular identity of lncRNA-0021 via exhaustive transcriptomic screening in AD models and human tissue","Establish whether plasma p-tau217 correlates with CNS lncRNA-0021 expression or extracellular release","Test exosome-mediated lncRNA-0021 delivery efficiency and dose-response relationship in vitro and in vivo","Validate downstream mechanism nodes: GSK-3β, NF-κB, and autophagy pathway modulation by lncRNA-0021"],"source":"debate_crux","hypotheses":["H1: lncRNA-0021 corresponds to a computationally predicted or orphan lncRNA transcript that can be isolated and sequenced from AD-relevant biological sources","H2: Exosomes isolated from candidate therapeutic cells contain detectable lncRNA-0021 that can be quantified via qRT-PCR using transcript-specific primers","H3: Plasma p-tau217 levels correlate with tissue and/or exosomal lncRNA-0021 abundance, enabling biomarker-driven dosing","H4: Exosomal lncRNA-0021 delivery modulates GSK-3β phosphorylation, NF-κB nuclear translocation, and autophagy flux in neuronal cells"],"debate_type":"hypothesis_debate","est_cost_usd":85000.0,"persona_used":"Theorist","crux_question":"hypothesis chain depends on multiple unproven causal links with no evidence for any single node","key_weaknesses":["lncRNA-0021 is entirely undefined—no sequence, genomic coordinates, functional literature, or molecular identity exists in any public database","All proposed neuroprotective mechanisms (GSK-3β modulation, NF-κB pathway, autophagy enhancement) are attributed to an undefined entity","Without molecular identity, the hypothesis cannot be tested, falsified, or progressed to therapeutic development","lncRNAs are typically intracellular effectors—exosome packaging, BBB penetration, and intracellular delivery represent substantial and unproven technical hurdles","No evidence that p-tau217 levels reliably predict BBB permeability or exosome CNS delivery efficiency"],"_schema_version":1,"hypothesis_title":"Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-0021 Therapeutic Window in AD","protocol_summary":"Phase 1 - Molecular Identity Discovery (Weeks 1-6): Perform exhaustive transcriptomic analysis using RNA-seq on: (a) frontal cortex tissue from AD (n=10) and age-matched controls (n=10) from ROSMAP; (b) exosomes isolated from plasma of these same subjects via ultracentrifugation (100,000g, 18h) and CD9/CD81/CD63 immunocapture; (c) neuronal cell lines (SH-SY5Y, iPSC-derived neurons) under stress conditions (okadaic acid 5nM for 24h to induce tau hyperphosphorylation). Bioinformatically filter for annotated lncRNA loci (Ensembl GRCh38) and orphan transcripts (lncRNA-0021 naming convention suggests a predicted/putative identifier). Design qRT-PCR assays flanking three distinct genomic regions of candidate transcripts. Confirm specificity via Sanger sequencing and RACE (5' and 3') to obtain full-length sequences.\n\nPhase 2 - Biomarker Correlation Analysis (Weeks 4-8): Conduct targeted qRT-PCR quantification of lncRNA-0021 candidate(s) in: (a) matched brain tissue RNA extracts (AD vs control); (b) plasma-derived exosomal RNA; (c) cortical neuronal cell lysates. Perform Spearman correlation against available plasma p-tau217 (SIMOA) and CSF p-tau217 measurements from same subjects. Establish whether lncRNA-0021 expression rises or falls with AD pathology burden.\n\nPhase 3 - Exosome Dosing Validation (Weeks 7-12): Engineer exosomes from HEK293T cells via ultracentrifugation, loading lncRNA-0021 via electroporation (Amaxa 4D, pulse code EO-115). Dose iPSC-derived cortical neurons with graded exosome concentrations (0, 10^7, 10^8, 10^9 particles/mL) 24h post okadaic acid treatment (5nM). Harvest cells at 6h, 24h, 48h, 72h post-dose. Assess: (a) intracellular lncRNA-0021 uptake via qRT-PCR and fluorescence in situ hybridization (FISH); (b) GSK-3β Ser9-phosphorylation via Western blot; (c) NF-κB p65 nuclear translocation via immunofluorescence confocal microscopy; (d) LC3-II/LC3-I ratio and p62 degradation as autophagy flux markers. Define dose-response curves and therapeutic window parameters.\n\nPhase 4 - In Vivo Proof-of-Concept (Weeks 10-14, optional extension): Administer lncRNA-0021-loaded exosomes to 5xFAD mice via tail vein injection at matched to plasma p-tau217-correlated doses vs fixed doses. Assess brain penetration via qRT-PCR of brain tissue, neuroinflammatory markers, and cognitive behavioral testing (Morris water maze).","debate_session_id":"sess_hypdebate_h_cef0dd34_20260426_164432","synthesis_summary":"This hypothesis is fundamentally untestable due to critical undefined components. While the concept of biomarker-triggered exosome dosing for CNS delivery has mechanistic merit, the core therapeutic entity lncRNA-0021 has no molecular identity in published literature—no sequence, genomic coordinates, or functional characterization exists. The biomarker rationale for p-tau217 reflects genuine disease activity but cannot compensate for the absence of a defined therapeutic target. Without molecular","est_duration_weeks":14.0,"dataset_dependencies":["Allen Brain Atlas adult human brain transcriptome (RNA-seq data)","ROSMAP/MSBB Banner longitudinal aging cohorts (frontal cortex RNA-seq, proteomics, p-tau217 plasma measures)","GSE153456 (AD exosome small/lncRNA sequencing dataset)","Human Protein Atlas lncRNA expression compendium"],"falsification_criteria":"F1: RNA-seq across all AD and control samples (brain, exosomes, stressed neurons) fails to identify any transcript matching the lncRNA-0021 locus/nomenclature within detection limits (≥1 transcript per million, TPM). F2: Candidate lncRNA transcripts identified show no correlation with plasma p-tau217 (Spearman |ρ| < 0.3, p > 0.10). F3: Exosomal delivery of lncRNA-0021 candidate fails to produce detectable intracellular uptake in neurons above baseline (<2-fold change vs mock). F4: None of the three proposed downstream mechanisms (GSK-3β, NF-κB, autophagy) show statistically significant changes (p > 0.05, ANOVA with Bonferroni correction) across any dose level. F5: Significant cytotoxicity (cell viability <70% by MTT/PrestoBlue) observed at the lowest exosome dose, eliminating any therapeutic window. If any two of F1-F5 are met, the hypothesis chain is falsified; if F1 alone is met (no molecular identity exists), the entire hypothesis is irreparably falsified regardless of other results.","predicted_observations":"If H1-H4 are supported: RNA-seq will identify a specific transcript corresponding to the lncRNA-0021 nomenclature, with sequence validated by RACE; qRT-PCR will show detectable lncRNA-0021 in AD brain tissue and exosomes with expression levels correlating positively with plasma p-tau217 (Spearman ρ > 0.5, p < 0.05); exosomal lncRNA-0021 uptake will be dose-dependent in neurons; GSK-3β phosphorylation will decrease significantly at the highest doses (e.g., p-GSK-3β/GSK-3β ratio reduced by ≥40%); NF-κB nuclear translocation will be inhibited (p65 nuclear/cytoplasmic ratio reduced by ≥30%); autophagy markers will show increased LC3-II/LC3-I ratio and decreased p62. The therapeutic window (defined as gap between lowest effective dose and highest dose before cytotoxicity) will be quantifiable.\n\nIf H1 is falsified: No transcript will be detectable matching lncRNA-0021 criteria in any AD or control tissue or exosomes, indicating the entity does not exist as proposed."},"created_at":"2026-04-27T01:55:00.986870-07:00","updated_at":"2026-04-27T01:55:00.986870-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":null,"citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"56964c09-35d4-422e-9544-ad5b03b437a0","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"crux_generator:theorist"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[],"incoming_links":[{"source_artifact_id":"open_question-53b299ad-42ec-4ec0-9a63-362506546741","link_type":"discriminating_experiment","strength":0.8,"evidence":"{\"confidence\": 0.8, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"source_artifact_id":"open_question-1aa28c4e-6a34-4330-bf1c-914119cb08d7","link_type":"discriminating_experiment","strength":0.6,"evidence":"{\"confidence\": 0.6, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"source_artifact_id":"open_question-6f8bfbff-f48a-41b3-9c07-106ea65350c6","link_type":"candidate_answer","strength":0.85,"evidence":"{\"confidence\": 0.85, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"source_artifact_id":"open_question-3d912899-2516-49ac-bd36-b539cdca4b11","link_type":"candidate_answer","strength":0.78,"evidence":"{\"confidence\": 0.78, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"}],"current_artifact_id":"experiment_proposal-e5b45059-f361-45a3-8ed0-f972ded65df8","is_canonical":true,"supersede_chain":["experiment_proposal-e5b45059-f361-45a3-8ed0-f972ded65df8"]}